•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Alamar Biosciences, a portfolio company of Qiming Venture Partners and a precision proteomics company, successfully listed on the NASDAQ Stock Exchange on April 17, 2026 (Beijing Time). Alamar (NASDAQ: ALMR) issued shares at $17 per share and opened at $22.6 per share, with a market capitalization of approximately $1.5 billion.
Qiming Venture Partners led Alamar’s Series A financing in 2020 and continued to fund the company’s development through subsequent Series B and Series C rounds. Prior to the IPO, Qiming Venture Partners held an approximately 19.2% stake in Alamar and was one of the company’s key institutional investors.
Founded in 2018, Alamar is a commercial-stage proteomics company focused on developing and commercializing proteomics technologies and establishing standards in protein detection and analysis. The company’s self-developed NULISA™ technology is designed to provide ultra-high sensitivity and high specificity, flexible multiplex protein detection, broad dynamic range, and seamless automation for detecting protein biomarkers at extremely low concentrations.
Alamar also developed ARGO™ HT, a fully automated, high-throughput system that supports a “sample-to-answer” workflow intended to accelerate product market penetration. As of the end of 2025, the ARGO™ HT system had an installed base of over 100 instruments, serving more than 300 customers across 25 countries. Since commercialization of its platform, the number of scientific articles published based on its technologies and products has exceeded 100.
William Hu, Managing Partner of Qiming Venture Partners, said: “Congratulations to Alamar on its successful listing. We firmly believe that ultra-high-sensitivity proteomics will innovatively transform the future of early disease screening and precision diagnostics.” He added that Qiming Venture Partners supported the company from early stages through its growth and expects Alamar’s proteomics platform to help deliver earlier, more accurate, and more accessible precision diagnostics.
Qiming Venture Partners was founded in 2006. The firm manages eleven US Dollar funds and seven RMB funds, with $9.5 billion in capital raised. Since its establishment, it has invested in technology and healthcare companies at early and growth stages, and has backed more than 580 companies. According to the company, over 210 portfolio companies have achieved exits through IPOs on exchanges including the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, and Shenzhen Stock Exchange, as well as through M&A or other means. The firm also states that more than 80 portfolio companies have achieved unicorn or super unicorn status.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
